---
figid: PMC3338341__gr2
figlink: /pmc/articles/PMC3338341/figure/fig2/
number: Figure 2
caption: Schematic diagram of mechanisms of activation of HH signaling in hematological
  cancers. Both paracrine and autocrine activation of HH signaling has been observed
  in hematological cancers (paracrine mainly in CLL and plasma cell myeloma, and both
  paracrine and autocrine in DLBCL). An autocrine mechanism of activation has also
  been reported in acute myeloid leukemia and in ALK-positive anaplastic large cell
  lymphoma (ALKL+ALCL). Activation of PI3K-AKT (activation of other oncogenic pathways
  not shown) contributes to the activation of HH signaling. NPM-ALK in ALK-positive
  ALCL enhances the stability and consequently the transcriptional activity of GLI1
  through activation of PI3K-AKT signaling. Examples of HH inhibitors, either natural
  products or synthetic compounds are shown (red boxes). 5E1 and robotnikinin bind
  and inactivate HH ligands, cyclopamine and GDC-0499 bind and inactivate SMO, and
  GANT-61 and HPI-1 interfere with GLI transcriptional activity.
pmcid: PMC3338341
papertitle: Aberrant Activation of the Hedgehog Signaling Pathway in Malignant Hematological
  Neoplasms.
reftext: Chi Young Ok, et al. Am J Pathol. 2012 Jan;180(1):2-11.
pmc_ranked_result_index: '68600'
pathway_score: 0.9467524
filename: gr2.jpg
figtitle: Mechanisms of activation of HH signaling in hematological cancers
year: '2012'
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3338341__gr2.html
  '@type': Dataset
  description: Schematic diagram of mechanisms of activation of HH signaling in hematological
    cancers. Both paracrine and autocrine activation of HH signaling has been observed
    in hematological cancers (paracrine mainly in CLL and plasma cell myeloma, and
    both paracrine and autocrine in DLBCL). An autocrine mechanism of activation has
    also been reported in acute myeloid leukemia and in ALK-positive anaplastic large
    cell lymphoma (ALKL+ALCL). Activation of PI3K-AKT (activation of other oncogenic
    pathways not shown) contributes to the activation of HH signaling. NPM-ALK in
    ALK-positive ALCL enhances the stability and consequently the transcriptional
    activity of GLI1 through activation of PI3K-AKT signaling. Examples of HH inhibitors,
    either natural products or synthetic compounds are shown (red boxes). 5E1 and
    robotnikinin bind and inactivate HH ligands, cyclopamine and GDC-0499 bind and
    inactivate SMO, and GANT-61 and HPI-1 interfere with GLI transcriptional activity.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PRKACA
  - PIK3CG
  - PIK3R6
  - PRKACG
  - PRKAR2B
  - CCND2
  - SMO
  - ALK
  - PRKACB
  - PIK3R3
  - PIK3R4
  - PIK3CD
  - PIK3R5
  - PRKAR1A
  - CCND1
  - ABCG2
  - PIK3CB
  - SHH
  - IHH
  - BCL2
  - PTCH1
  - CSNK1A1
  - PRKAR1B
  - DHH
  - PRKAR2A
  - PIK3CA
  - GSK3B
  - GLI1
  - Cyclopamine
  - Cancer
genes:
- word: PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKACA
  entrez: '5566'
- word: PI3K/AKTT
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: PI3K/AKTT
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKACG
  entrez: '5568'
- word: PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKAR2B
  entrez: '5577'
- word: CCND2
  symbol: CCND2
  source: hgnc_symbol
  hgnc_symbol: CCND2
  entrez: '894'
- word: SMO
  symbol: SMO
  source: hgnc_symbol
  hgnc_symbol: SMO
  entrez: '6608'
- word: ALK+
  symbol: ALK
  source: hgnc_symbol
  hgnc_symbol: ALK
  entrez: '238'
- word: PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKACB
  entrez: '5567'
- word: PI3K/AKTT
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: PI3K/AKTT
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: PI3K/AKTT
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: PI3K/AKTT
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKAR1A
  entrez: '5573'
- word: CCND1,ABCG2
  symbol: CCND1
  source: hgnc_symbol
  hgnc_symbol: CCND1
  entrez: '595'
- word: CCND1,ABCG2
  symbol: ABCG2
  source: hgnc_symbol
  hgnc_symbol: ABCG2
  entrez: '9429'
- word: PI3K/AKTT
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: (SHH,IHH,DHH)
  symbol: SHH
  source: hgnc_symbol
  hgnc_symbol: SHH
  entrez: '6469'
- word: (SHH,IHH,DHH)
  symbol: IHH
  source: hgnc_symbol
  hgnc_symbol: IHH
  entrez: '3549'
- word: BCL2
  symbol: BCL2
  source: hgnc_symbol
  hgnc_symbol: BCL2
  entrez: '596'
- word: PTCH
  symbol: PTCH
  source: hgnc_prev_symbol
  hgnc_symbol: PTCH1
  entrez: '5727'
- word: CK1
  symbol: CK1
  source: hgnc_alias_symbol
  hgnc_symbol: CSNK1A1
  entrez: '1452'
- word: PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKAR1B
  entrez: '5575'
- word: DHH)
  symbol: DHH
  source: hgnc_symbol
  hgnc_symbol: DHH
  entrez: '50846'
- word: PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKAR2A
  entrez: '5576'
- word: PI3K/AKTT
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: GSK3B
  symbol: GSK3B
  source: hgnc_symbol
  hgnc_symbol: GSK3B
  entrez: '2932'
- word: (GLI1/23
  symbol: GLI1
  source: hgnc_symbol
  hgnc_symbol: GLI1
  entrez: '2735'
chemicals:
- word: Cyclopamine
  source: MESH
  identifier: C000541
diseases:
- word: Cancer
  source: ''
  identifier: ''
---
